With further clarification of the overactivated pathway of TLR9/TGF-β1/PDGF-B in LN patients, it is critical to study TLR9, TGF-β1, or PDGF-B antagonists in the prevention and treatment of LN. This evidence concerns the gene PDGFB and lobular neoplasia.